Why Is Twist Bioscience (TWST) Stock Down -7.07% Today?
Key Takeaways
- TWST shares fell 7.07% to $134.28, down from the prior session's close of $144.49.
- The decline reflects a sharp unwind of the AI-driven biotech rally, with investors taking profits after a more than 355% year-to-date run.
- Persistent selling by ARK Invest — which has now unloaded shares for 21 consecutive sessions — and recent insider sales have amplified bearish sentiment.
- A cautious new Wall Street initiation (Jefferies' Hold rating) reinforced concerns that the stock is already priced for flawless execution.
- Broader pressure on high-growth, high-valuation AI names added fuel to the pullback.
Opening Summary
Twist Bioscience Corporation (TWST), a South San Francisco-based synthetic biology company that manufactures custom DNA and next-generation sequencing tools for drug discovery, diagnostics, and research, saw its shares slide sharply in today's session. The stock fell 7.07% to $134.28, compared with a previous close of $144.49, as investors locked in gains following an extraordinary multi-month rally. The market reaction centered on a cooling of the broader AI trade, sustained institutional selling, and fresh questions about the stock's valuation rather than any new company-specific fundamental shock.
Profit-Taking After a Massive AI-Fueled Rally
The primary driver behind today's move is the unwinding of the AI hype trade that has powered TWST to remarkable heights in 2026. The stock is up more than 355% year to date and trades within a 52-week range of $23.30 to $219.71. After such a steep ascent, the shares became vulnerable to a valuation reset, and today's selloff reflects investors reassessing what they are willing to pay for richly priced, unprofitable growth names. Twist's position at the intersection of synthetic biology and AI-enabled drug discovery made it a magnet for momentum capital on the way up — and equally exposed when sentiment turned.
Sustained ARK Invest Selling and Insider Activity
Compounding the profit-taking, ARK Invest has now sold TWST shares for 21 consecutive sessions, a persistent de-risking across its healthcare and innovation ETFs that has weighed heavily on investor confidence. The extended institutional distribution, combined with a series of insider transactions over recent months — many tied to tax obligations on vested equity — has reinforced the perception that the latest run-up may have outpaced fundamentals. While modest relative to the company's market capitalization, the pattern of selling has had an outsized effect on sentiment for a stock with a beta near 2.2 and a reputation for high volatility.
Valuation Concerns and Cautious Analyst Coverage
Wall Street's mixed messaging has added to the turbulence. Jefferies recently initiated coverage of TWST with a Hold rating and a $150 price target, cautioning that the stock is already priced for very strong execution — a notable contrast to more bullish targets from firms like Barclays and Guggenheim. The divergence underscores how divided analysts remain on how much upside is left. With the company still generating operating losses and burning cash despite strong revenue growth, any reassessment of the valuation premium attached to AI-adjacent biotech names translates quickly into selling pressure.
Market Context and Trading Activity
The decline in TWST is consistent with a broader de-risking across high-growth biotechnology and AI-linked equities rather than an isolated event. The stock has been trading below its 50-day moving average of roughly $147, confirming a near-term technical breakdown even as it remains well above its 200-day moving average. Trading activity reflected distribution rather than a quiet drift, with volume running elevated relative to typical daily averages as sellers pressed the name. Notably, the move diverged from the broader market, which has held comparatively steady — an indication that today's weakness is concentrated in momentum-sensitive growth sectors and specific to the stock's own extended valuation profile.
What Comes Next for TWST
Looking ahead, investors will be watching whether the AI-enabled drug discovery narrative that fueled the rally can translate into sustained margin expansion and a clearer path toward profitability. Twist has posted steady revenue growth and improving manufacturing efficiency, but persistent losses and cash burn remain the central risk. Upcoming earnings, continued updates on ARK Invest's positioning, and any shift in the broader appetite for AI-adjacent growth stocks will likely dictate the next leg of trading. Given the stock's high beta and the distance it still trades above long-term moving averages, further volatility should be expected even as the longer-term synthetic biology story remains intact.
Trending AI Robots
For traders seeking a systematic edge in fast-moving markets like this, Tickeron's Trending AI Robots page curates the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI bots covering thousands of tickers, with each bot differing by strategy, timeframe, performance metrics, and the symbols it trades. Only the top performers are featured in this section, helping users identify approaches that are working right now. Explore the Trending AI Robots to see which strategies are leading today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TWST's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for TWST moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 instances where the indicator moved out of the overbought zone. In 42 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 71 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
TWST moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 233 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 186 of 228 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.738) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement